These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 35840465)
1. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. Klein EA; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Stovsky M Urol Oncol; 2022 Sep; 40(9):408.e9-408.e18. PubMed ID: 35840465 [TBL] [Abstract][Full Text] [Related]
2. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176 [TBL] [Abstract][Full Text] [Related]
3. Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. Stovsky M; Klein EA; Chait A; Manickam K; Stephenson AJ; Wagner M; Dineen M; Lotan Y; Partin A; Baniel J; Kestranek A; Gawande P; Boris Zaslavsky J Urol; 2019 Jun; 201(6):1115-1120. PubMed ID: 30810464 [TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H; Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509 [TBL] [Abstract][Full Text] [Related]
5. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214 [TBL] [Abstract][Full Text] [Related]
6. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023 [TBL] [Abstract][Full Text] [Related]
7. IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study. Scovell JM; Stovsky M; Partin A; Lotan Y; Baniel J; Dineen M; Hafron J; Manickam K; Pliskin M; Wagner M; Kestranek A; Klein EA Urology; 2023 May; 175():132-136. PubMed ID: 36804443 [TBL] [Abstract][Full Text] [Related]
8. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM; JAMA Oncol; 2024 Jun; 10(6):726-736. PubMed ID: 38635241 [TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502 [TBL] [Abstract][Full Text] [Related]
10. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277 [TBL] [Abstract][Full Text] [Related]
11. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese men. Tang P; Du W; Xie K; Deng X; Fu J; Chen H; Yang W Urol Oncol; 2013 Aug; 31(6):744-8. PubMed ID: 21868261 [TBL] [Abstract][Full Text] [Related]
12. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035 [TBL] [Abstract][Full Text] [Related]
13. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565 [TBL] [Abstract][Full Text] [Related]
14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884 [TBL] [Abstract][Full Text] [Related]
15. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
16. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Vessella RL; Lange PH; Partin AW; Chan DW; Sokoll LJ; Sasse EA; Crawford ED Urology; 2000 Jun; 55(6):909-14. PubMed ID: 10840107 [TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]
18. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570 [TBL] [Abstract][Full Text] [Related]